DK2361090T3 - Sammensætninger til behandling af centralt medieret kvalme og opkastning - Google Patents

Sammensætninger til behandling af centralt medieret kvalme og opkastning

Info

Publication number: DK2361090T3
Authority: DK; Denmark
Prior art keywords: vomiting; nurse; compositions; treating central; central mediated
Prior art date: 2009-11-18

Application number

DK10805301.8T

Other languages

English (en)

Inventor

Fabio Trento

Roberta Cannella

Daniele Bonadeo

Riccardo Braglia

Sergio Cantoreggi

Giorgia Rossi

Original Assignee

Helsinn Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-18

Filing date

2010-11-18

Publication date

2014-08-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2361090(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-18 Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa

2014-08-25 Application granted granted Critical

2014-08-25 Publication of DK2361090T3 publication Critical patent/DK2361090T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Paints Or Removers (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK10805301.8T 2009-11-18 2010-11-18 Sammensætninger til behandling af centralt medieret kvalme og opkastning DK2361090T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26247009P	2009-11-18	2009-11-18
US38270910P	2010-09-14	2010-09-14
PCT/IB2010/003106 WO2011061622A1 (en)	2009-11-18	2010-11-18	Compositions for treating centrally mediated nausea and vomiting

Publications (1)

Publication Number	Publication Date
DK2361090T3 true DK2361090T3 (da)	2014-08-25

Family

ID=43608757

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK10805301.8T DK2361090T3 (da)	2009-11-18	2010-11-18	Sammensætninger til behandling af centralt medieret kvalme og opkastning
DK14151683.1T DK2722045T3 (da)	2009-11-18	2010-11-18	Præparater til behandling af centralt medieret kvalme og opkastning

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK14151683.1T DK2722045T3 (da)	2009-11-18	2010-11-18	Præparater til behandling af centralt medieret kvalme og opkastning

Country Status (40)

Country	Link
US (1)	US12042494B2 (da)
EP (3)	EP2727590B1 (da)
JP (1)	JP5890780B2 (da)
KR (1)	KR101615108B1 (da)
CN (6)	CN102655864A (da)
AP (1)	AP3083A (da)
AU (1)	AU2010320598B2 (da)
BR (1)	BR112012011485B1 (da)
CA (1)	CA2778301C (da)
CL (1)	CL2012001276A1 (da)
CO (1)	CO6551693A2 (da)
CR (1)	CR20120216A (da)
CU (1)	CU24048B1 (da)
CY (1)	CY1118062T1 (da)
DK (2)	DK2361090T3 (da)
DO (1)	DOP2012000138A (da)
EA (1)	EA026815B1 (da)
EC (1)	ECSP12011907A (da)
ES (4)	ES2494015T3 (da)
GE (1)	GEP20156226B (da)
GT (1)	GT201200156A (da)
HK (2)	HK1214148A1 (da)
HR (3)	HRP20140759T1 (da)
HU (1)	HUE029677T2 (da)
IL (1)	IL219576A (da)
LT (1)	LT2722045T (da)
MA (1)	MA33810B1 (da)
MX (1)	MX2012005347A (da)
MY (1)	MY159393A (da)
NI (1)	NI201200090A (da)
NZ (1)	NZ599439A (da)
PE (1)	PE20121483A1 (da)
PH (1)	PH12012500887A1 (da)
PL (3)	PL2722045T3 (da)
PT (2)	PT2722045T (da)
RS (2)	RS55206B1 (da)
SI (2)	SI2722045T1 (da)
SM (1)	SMT201400112B (da)
TN (1)	TN2012000170A1 (da)
WO (1)	WO2011061622A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2722045B1 (en)	2009-11-18	2016-07-06	Helsinn Healthcare SA	Compositions for treating centrally mediated nausea and vomiting
DK2361090T3 (da)	2009-11-18	2014-08-25	Helsinn Healthcare Sa	Sammensætninger til behandling af centralt medieret kvalme og opkastning
NO2729147T3 (da) *	2011-07-04	2018-02-03
CN106974912A (zh) *	2011-10-18	2017-07-25	赫尔辛医疗股份公司	奈妥匹坦和帕洛诺司琼的治疗性组合
US9403772B2 (en)	2011-11-29	2016-08-02	Helsinn Healthcare Sa	4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en)	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect
CN103520725B (zh) *	2012-07-05	2017-10-24	海思科医药集团股份有限公司	一种治疗呕吐的药物组合物
KR20250136946A (ko)	2015-03-04	2025-09-16	반다 파마슈티칼즈, 인코퍼레이티드.	트라디피턴트에 의한 치료 방법
CN106902086B (zh) *	2015-12-23	2020-10-20	江苏恒瑞医药股份有限公司	一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) *	2016-11-01	2016-12-14	Acacia Pharma Ltd	method
GB201702250D0 (en)	2017-02-10	2017-03-29	Acacia Pharma Ltd	Method
CN108721214B (zh) *	2017-04-14	2020-06-16	和龙	奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) *	2017-05-15	2018-11-23	和龙	奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) *	2017-07-04	2019-01-15	南京诺瑞特医药科技有限公司	含有奈妥吡坦的微乳制剂
CN111343981A (zh) *	2017-11-17	2020-06-26	万达制药公司	使用川地匹坦治疗胃肠疾病的方法
US20200368166A1 (en) *	2018-02-02	2020-11-26	Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)	Oral Formulations And Uses Thereof
WO2022135549A1 (zh) *	2020-12-25	2022-06-30	上海盛迪医药有限公司	Nk1拮抗剂前药化合物与5-ht3受体拮抗剂的联用用途
EP4385500A1 (en)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Fixed dose combination comprising netupitant and palonosetron
EP4633612A1 (en)	2022-12-12	2025-10-22	Alfred E. Tiefenbacher (GmbH & Co. KG)	Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4633608A1 (en)	2022-12-12	2025-10-22	Alfred E. Tiefenbacher (GmbH & Co. KG)	Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU642178B2 (en)	1989-11-28	1993-10-14	Roche Palo Alto Llc	New tricyclic compounds
US5510486A (en)	1994-07-26	1996-04-23	Syntex (U.S.A.) Inc.	Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en)	1995-11-10	2001-10-02	The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland	Calixarenes and their use for sequestration of metals
ATE496032T1 (de)	1999-02-24	2011-02-15	Hoffmann La Roche	4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
ATE400556T1 (de)	2000-07-14	2008-07-15	Hoffmann La Roche	N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
AU1608502A (en)	2000-12-14	2002-06-24	Hoffmann La Roche	Self emulsifying lipid matrix (selm)
DE10393729T5 (de)	2002-11-15	2005-10-13	Helsinn Healthcare S.A.	Verfahren zur Behandlung von Emesis
JO2735B1 (en)	2003-01-30	2013-09-15	هيلسين هيلث كير أس ايه.	Liquid pharmaceutical formations of balloonosterone
MY143789A (en) *	2003-02-18	2011-07-15	Helsinn Healthcare Sa	Use of palonosetron treating post- operative nausea and vomiting
CN1767830A (zh) *	2003-04-08	2006-05-03	普罗热尼奇制药公司	外周阿片拮抗剂具体是甲基纳曲酮治疗肠易激综合征的用途
MX2007009571A (es)	2005-02-25	2007-09-21	Hoffmann La Roche	Tabletas con dispersion mejorada de la sustancia del farmaco.
US7479312B2 (en)	2005-07-07	2009-01-20	Konica Minolta Opto, Inc.	Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
SG185849A1 (en)	2006-02-23	2012-12-28	Pfizer Ltd	Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
KR101441459B1 (ko) *	2006-10-24	2014-09-18	헬신 헬쓰케어 에스.에이.	안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐
WO2009005673A1 (en) *	2007-06-28	2009-01-08	Schering Corporation	Anti-igf1r
CA2709827A1 (en) *	2007-12-18	2009-06-25	Schering Corporation	Biomarkers for sensitivity to anti-igf1r therapy
DK2361090T3 (da)	2009-11-18	2014-08-25	Helsinn Healthcare Sa	Sammensætninger til behandling af centralt medieret kvalme og opkastning

2010
- 2010-11-18 DK DK10805301.8T patent/DK2361090T3/da active
- 2010-11-18 PE PE2012000686A patent/PE20121483A1/es active IP Right Grant
- 2010-11-18 EA EA201290356A patent/EA026815B1/ru active Protection Beyond IP Right Term
- 2010-11-18 CA CA2778301A patent/CA2778301C/en active Active
- 2010-11-18 RS RS20160833A patent/RS55206B1/sr unknown
- 2010-11-18 SI SI201031291T patent/SI2722045T1/sl unknown
- 2010-11-18 CN CN2010800521070A patent/CN102655864A/zh active Pending
- 2010-11-18 PL PL14151683T patent/PL2722045T3/pl unknown
- 2010-11-18 EP EP14151676.5A patent/EP2727590B1/en active Active
- 2010-11-18 HU HUE14151683A patent/HUE029677T2/hu unknown
- 2010-11-18 CN CN201510046972.9A patent/CN104856998A/zh active Pending
- 2010-11-18 EP EP14151678.1A patent/EP2722044B1/en active Active
- 2010-11-18 PH PH1/2012/500887A patent/PH12012500887A1/en unknown
- 2010-11-18 PT PT141516831T patent/PT2722045T/pt unknown
- 2010-11-18 MX MX2012005347A patent/MX2012005347A/es active IP Right Grant
- 2010-11-18 CN CN201610795817.1A patent/CN107050455B/zh active Active
- 2010-11-18 CN CN201510047631.3A patent/CN104856999A/zh active Pending
- 2010-11-18 LT LTEP14151683.1T patent/LT2722045T/lt unknown
- 2010-11-18 CN CN201610797549.7A patent/CN106512010A/zh active Pending
- 2010-11-18 RS RSP20140423 patent/RS53491B1/sr unknown
- 2010-11-18 NZ NZ599439A patent/NZ599439A/en unknown
- 2010-11-18 ES ES10805301.8T patent/ES2494015T3/es active Active
- 2010-11-18 BR BR112012011485-9A patent/BR112012011485B1/pt active IP Right Grant
- 2010-11-18 ES ES14151678.1T patent/ES2623503T3/es active Active
- 2010-11-18 CN CN201610795827.5A patent/CN106421793B/zh active Active
- 2010-11-18 KR KR1020127015676A patent/KR101615108B1/ko active Active
- 2010-11-18 MY MYPI2012002073A patent/MY159393A/en unknown
- 2010-11-18 WO PCT/IB2010/003106 patent/WO2011061622A1/en not_active Ceased
- 2010-11-18 PT PT108053018T patent/PT2361090E/pt unknown
- 2010-11-18 ES ES14151683.1T patent/ES2595077T3/es active Active
- 2010-11-18 EP EP10805301.8A patent/EP2361090B1/en active Active
- 2010-11-18 ES ES14151676.5T patent/ES2559475T3/es active Active
- 2010-11-18 GE GEAP201012752A patent/GEP20156226B/en unknown
- 2010-11-18 SI SI201030688T patent/SI2361090T1/sl unknown
- 2010-11-18 PL PL10805301T patent/PL2361090T3/pl unknown
- 2010-11-18 HR HRP20140759AT patent/HRP20140759T1/hr unknown
- 2010-11-18 DK DK14151683.1T patent/DK2722045T3/da active
- 2010-11-18 JP JP2012539433A patent/JP5890780B2/ja active Active
- 2010-11-18 PL PL14151678T patent/PL2722044T3/pl unknown
- 2010-11-18 AU AU2010320598A patent/AU2010320598B2/en active Active
- 2010-11-18 AP AP2012006278A patent/AP3083A/xx active
2012
- 2012-04-13 TN TNP2012000170A patent/TN2012000170A1/en unknown
- 2012-04-26 CR CR20120216A patent/CR20120216A/es unknown
- 2012-05-03 IL IL219576A patent/IL219576A/en active IP Right Grant
- 2012-05-10 NI NI201200090A patent/NI201200090A/es unknown
- 2012-05-15 DO DO2012000138A patent/DOP2012000138A/es unknown
- 2012-05-16 CL CL2012001276A patent/CL2012001276A1/es unknown
- 2012-05-17 EC ECSP12011907 patent/ECSP12011907A/es unknown
- 2012-05-18 CU CU2012000078A patent/CU24048B1/es active IP Right Grant
- 2012-05-18 CO CO12082329A patent/CO6551693A2/es not_active Application Discontinuation
- 2012-05-18 GT GT201200156A patent/GT201200156A/es unknown
- 2012-06-11 MA MA34953A patent/MA33810B1/fr unknown
2014
- 2014-08-18 SM SM201400112T patent/SMT201400112B/xx unknown
2016
- 2016-02-24 HK HK16102110.3A patent/HK1214148A1/zh unknown
- 2016-02-24 HK HK16102109.6A patent/HK1214147A1/zh unknown
- 2016-10-05 CY CY20161100991T patent/CY1118062T1/el unknown
- 2016-10-05 HR HRP20161277TT patent/HRP20161277T1/hr unknown
2017
- 2017-03-14 HR HRP20170419TT patent/HRP20170419T1/hr unknown
2022
- 2022-12-16 US US18/082,737 patent/US12042494B2/en active Active

Also Published As

Publication number	Publication date
HRP20140759T1 (hr)	2014-10-24
CN107050455B (zh)	2020-09-29
CL2012001276A1 (es)	2012-12-07
ES2559475T3 (es)	2016-02-12
PL2722044T3 (pl)	2017-08-31
NI201200090A (es)	2012-11-13
EP2727590A1 (en)	2014-05-07
ECSP12011907A (es)	2012-10-30
GEP20156226B (en)	2015-01-26
HUE029677T2 (hu)	2017-03-28
US20230263799A1 (en)	2023-08-24
ES2494015T3 (es)	2014-09-12
ES2595077T3 (es)	2016-12-27
CN104856998A (zh)	2015-08-26
CU24048B1 (es)	2014-12-26
IL219576A (en)	2017-08-31
CA2778301C (en)	2016-06-14
PE20121483A1 (es)	2012-12-02
AP2012006278A0 (en)	2012-06-30
HRP20170419T1 (hr)	2017-06-02
EP2361090A1 (en)	2011-08-31
EP2722044A1 (en)	2014-04-23
CA2778301A1 (en)	2011-05-26
MA33810B1 (fr)	2012-12-03
CR20120216A (es)	2012-07-24
JP2013511507A (ja)	2013-04-04
MX2012005347A (es)	2012-08-03
WO2011061622A1 (en)	2011-05-26
CN106512010A (zh)	2017-03-22
RS55206B1 (sr)	2017-01-31
CO6551693A2 (es)	2012-10-31
EA026815B1 (ru)	2017-05-31
LT2722045T (lt)	2016-09-26
AU2010320598B2 (en)	2016-06-16
MY159393A (en)	2016-12-30
SI2361090T1 (sl)	2014-09-30
KR101615108B1 (ko)	2016-05-12
SMT201400112B (it)	2014-11-10
TN2012000170A1 (en)	2013-12-12
AP3083A (en)	2015-01-31
CN106421793A (zh)	2017-02-22
SI2722045T1 (sl)	2017-02-28
ES2623503T3 (es)	2017-07-11
PL2361090T3 (pl)	2014-10-31
DOP2012000138A (es)	2012-11-15
EP2722044B1 (en)	2017-01-04
HK1214147A1 (zh)	2016-07-22
PL2722045T3 (pl)	2017-03-31
EP2727590B1 (en)	2015-10-21
US12042494B2 (en)	2024-07-23
CY1118062T1 (el)	2017-06-28
EA201290356A1 (ru)	2012-12-28
NZ599439A (en)	2014-06-27
IL219576A0 (en)	2012-06-28
HK1214148A1 (zh)	2016-07-22
CN102655864A (zh)	2012-09-05
BR112012011485B1 (pt)	2021-06-29
KR20120101456A (ko)	2012-09-13
EP2361090B1 (en)	2014-05-21
GT201200156A (es)	2014-03-27
RS53491B1 (sr)	2015-02-27
PT2722045T (pt)	2016-10-18
PH12012500887A1 (en)	2016-08-26
DK2722045T3 (da)	2016-10-24
AU2010320598A1 (en)	2012-06-14
CN106421793B (zh)	2023-06-16
JP5890780B2 (ja)	2016-03-22
PT2361090E (pt)	2014-09-03
CN104856999A (zh)	2015-08-26
HRP20161277T1 (hr)	2016-11-18
BR112012011485A2 (pt)	2018-04-03
CU20120078A7 (es)	2012-10-15
CN107050455A (zh)	2017-08-18

Publication	Publication Date	Title
DK2361090T3 (da)	2014-08-25	Sammensætninger til behandling af centralt medieret kvalme og opkastning
DK2470656T3 (da)	2015-06-22	Sammensætning til hæmning af genekspression og anvendelser heraf
DK2323638T3 (da)	2014-08-11	Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK3795573T3 (da)	2022-09-19	Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK3128014T3 (da)	2020-02-17	Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger
DK2565193T3 (da)	2014-06-16	Sammensætninger og fremgangsmåder til hæmning af JAK-signalvejen
DK3181134T3 (da)	2020-01-20	Bifidobakterier til behandling af diabetes og relaterede tilstande
DK2419732T3 (da)	2019-12-16	Prionfrie nanopartikelsammensætninger og fremgangsmåder
DK2894165T5 (da)	2024-10-14	Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2445489T3 (da)	2020-01-27	Sammensætninger til behandling af narkotikamisbrug og forbedring af misbrugsrelateret adfærd
DK3460056T3 (da)	2020-11-09	Terapeutiske nukleasesammensætninger og fremgangsmåder
DK2513023T3 (da)	2020-01-13	Sammensætninger og anvendelser af cis-1,1,1,4,4,4-hexafluor-2-buten
DK2446246T3 (da)	2015-06-22	Indretning og fremgangsmåde til udvælgelse af partikler
DK2473034T3 (da)	2021-02-08	Frøbehandlingssammensætninger og fremgangsmåde
DK2437742T3 (da)	2014-11-03	Nye sammensætninger til behandling af cmt og beslægtede sygdomme
DK2419114T4 (da)	2019-05-27	Bakteriesammensætninger til profylakse og behandling af degenerative sygdomme
DK2247582T3 (da)	2017-01-02	Vandfri, krystallinsk form af dimethoxydocetaxel og fremgangsmåder til fremstilling heraf
DK2419670T3 (da)	2015-11-16	Leveringsmetode og sammensætninger
DK2504353T4 (da)	2023-11-20	Lipopeptidsammensætninger og tilsvarende fremgangsmåder
BR112012000525A2 (pt)	2015-09-15	inibidores da bace
DK2346552T4 (da)	2020-03-23	Lægemiddelafgivelsesanordning og fremgangsmåde til fremstilling af en lægemiddelafgivelsesanordning
DK3311823T3 (da)	2021-03-01	Fremgangsmåder og sammensætninger til brydning af biofilm ved hjælp af chitosan-derivatsammensætninger
DK2245032T3 (da)	2015-06-22	Folater, sammensætninger og anvendelser deraf
DK2513193T3 (da)	2014-01-27	Forbedrede blends af polyarylenethere og polyarylensulfider
DK3443957T3 (da)	2020-12-21	Forbindelser og sammensætninger til behandling af cancer